ClinicalTrials.Veeva

Menu

Seroprevalence of SARS-Cov-2 Antibodies in Children

Q

Queen's University Belfast

Status

Completed

Conditions

Corona Virus Infection
COVID
Multisystem Inflammatory Syndrome in Children

Treatments

Other: Blood Storage
Diagnostic Test: Covid-19 Antibody testing (IgG and IgM)

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

It is unknown what proportion of healthy children have been exposed to SARS-Cov-2 and how many have antibodies. The aim of this study is to follow a cohort of healthy children over six months and measure their antibodies to SARS-CoV-2.

Full description

Coronaviruses are non-segmented positive-stranded RNA viruses with a roughly 30 kb genome. The majority of coronaviruses cause disease in a specific host species but some have infected humans by cross-species transmission. This process has led to a number of severe outbreaks of human disease including severe acute respiratory syndrome (SARS) in 2003 and Middle East respiratory syndrome (MERS) in 2012.

From December 2019 a novel infection "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) was identified in the Wuhan region of China. The infection was identified as the causal factor in a growing number of severe cases of pneumonia. This disease was subsequently named coronavirus disease 2019 (COVID-19) by World Health Organisation (WHO). SARS-CoV-2 has been shown to cause severe disease similar to the previous SARS coronavirus from 2003. Severe disease is associated with pneumonia and damage to vital organs including lung, heart, liver, and kidney.

Fortunately SARS-CoV-2 appears to cause only mild, or no, symptoms in children.

The social distancing measures in the United Kingdom include the closure of schools and the cancelling of routine paediatric clinics. These drastic, but necessary, steps are likely to have a profound effect on the well-being of children.

This study is required to determine what proportion of children have been exposed to SARS-Cov-2 and how many, if any, have neutralizing antibodies. The findings from this study could be used to inform public health decisions regarding the re-opening of schools and other services vital to the well-being of children.

In addition the study will recruit children with paediatric multi-system inflammatory syndrome admitted to the Royal Belfast Hospital for Sick Children along with matched controls with other infections.

Enrollment

1,100 patients

Sex

All

Ages

1 month to 15 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Healthy children of healthcare professionals.

Exclusion Criteria:

Not currently receiving antibiotics, not admitted to hospital within the last seven days, not receiving immunosuppressive drugs and never diagnosed with a malignancy.

Admitted children with paediatric multisystem inflammatory syndrome and admitted children with other serious infections.

Trial design

1,100 participants in 3 patient groups

Healthy Children
Description:
Healthy children of healthcare workers between 2 and 15 years of age
Treatment:
Other: Blood Storage
Diagnostic Test: Covid-19 Antibody testing (IgG and IgM)
Paediatric Multisystem Inflammatory Syndrome
Description:
Children admitted to hospital with Paediatric Multisystem Inflammatory Syndrome
Treatment:
Other: Blood Storage
Diagnostic Test: Covid-19 Antibody testing (IgG and IgM)
Serious Infection
Description:
Children admitted to hospital with serious infections
Treatment:
Other: Blood Storage
Diagnostic Test: Covid-19 Antibody testing (IgG and IgM)

Trial documents
1

Trial contacts and locations

5

Loading...

Central trial contact

Thomas Waterfield, BMBCh; Sharon Christie, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems